Post-authorisation safety study to assess the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes: a multi-database European study (PASS DiabCancer)

16/12/2016
31/10/2025
EU PAS number:
EUPAS16424
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

ER-9521_protocol_1245-0097_version3

English (969.84 KB - PDF) View document
Updated protocol

1245-0097 Final protocol v8.0_Redacted.pdf

First published: 15/01/2025
English (2.68 MB - PDF) View document
Study results
Study results

1245-0097_Synopsis.pdf

English (246.17 KB - PDF) View document
Study report
Other information